Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Linaprazan
Therapeutic Area : Gastroenterology
Study Phase : Phase II
Sponsor : Fourth Swedish National Pension Fund
Deal Size : $25.6 million
Deal Type : Financing
Details : The proceeds from the financing round will be used to perform a phase 2 clinical trial, which is expected to start in the second half of 2020.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
April 03, 2020
Lead Product(s) : Linaprazan
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II
Sponsor : Fourth Swedish National Pension Fund
Deal Size : $25.6 million
Deal Type : Financing
Reset All
